[The significance of quality of life from a socio-legal perspective].
Only rarely is the term quality of life explicitly mentioned in the Social Security Code (Sozialgesetzbuch, SGB). In the statutory health insurance law (Book V of the Social Security Code, SGB V), the term is explicitly regulated within the context of the entitlement to pharmaceuticals. While there are pharmaceuticals that have the priority to increase the quality of life but are excluded from the provision of healthcare (Section 34 (1) Sentence 7 SGB V), the improvement of the quality of life has to be taken into account for the cost-benefit assessment (Section 35b SGB V) as well as for the early pharmaceutical benefit assessment (Section 35a SGB V) and for the formation of reference price groups (Section 35 SGB V) for and in the case of an entitlement to benefits in the event of illness.
Universität Heidelberg, Juristische Fakultät. Electronic address: axer@jurs.uni-heidelberg.de.
Peter
P
Axer
D003362:Cost-Benefit Analysis / Q000191:economics; D016527:Drug Costs / Q000331:legislation & jurisprudence; D005858:Germany; D006297:Health Services Accessibility / Q000191:economics / Q000331:legislation & jurisprudence; D006801:Humans; D019458:Insurance Coverage / Q000331:legislation & jurisprudence; D009313:National Health Programs / Q000191:economics / Q000331:legislation & jurisprudence*; D055553:Prescription Drugs / Q000191:economics / Q000627:therapeutic use; D011788:Quality of Life / Q000331:legislation & jurisprudence* / Q000523:psychology*; D012943:Social Security / Q000191:economics / Q000331:legislation & jurisprudence*; D019564:Unnecessary Procedures / Q000191:economics
D055553:Prescription Drugs
Arzneimittelausschluss; Arzneimittelnutzenbewertung; Krankheit; Lebensqualität; exclusion of pharmaceuticals; gesetzliche Krankenversicherung; illness; pharmaceutical benefit assessment; quality of life; statutory health insurance